These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 22527342)

  • 1. Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment.
    Statkevich P; Kosoglou T; Preston RA; Kumar B; Xuan F; Trusley C; Schiller JE; Langdon RB; Cutler DL
    Eur J Clin Pharmacol; 2012 Nov; 68(11):1501-8. PubMed ID: 22527342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease.
    Kosoglou T; Kraft WK; Kumar B; Statkevich P; Xuan F; Ma L; Jennings LK; Schiller JE; Langdon RB; Cutler DL
    Eur J Clin Pharmacol; 2012 Jul; 68(7):1049-56. PubMed ID: 22315147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No Pharmacokinetic Drug-Drug Interaction Between Prasugrel and Vorapaxar Following Multiple-Dose Administration in Healthy Volunteers.
    Anderson MS; Kosoglou T; Statkevich P; Li J; Rotonda J; Meehan AG; Cutler DL
    Clin Pharmacol Drug Dev; 2018 Feb; 7(2):143-150. PubMed ID: 28403576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of vorapaxar and its metabolite following oral administration in healthy Chinese and American subjects.
    Chen X; Kosoglou T; Statkevich P; Kumar B; Li J; Dockendorf MF; Wang G; Lowe RS; Jiang J; Liu H; Wang Z; Cutler DL; Hu P
    Int J Clin Pharmacol Ther; 2014 Oct; 52(10):889-99. PubMed ID: 25138682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects.
    Kosoglou T; Reyderman L; Tiessen RG; van Vliet AA; Fales RR; Keller R; Yang B; Cutler DL
    Eur J Clin Pharmacol; 2012 Mar; 68(3):249-58. PubMed ID: 21935705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics of rosiglitazone.
    Kosoglou T; Kumar B; Statkevich P; Schiller JE; Kantesaria B; Hanson ME; Sisk CM; Cutler DL
    Clin Pharmacol Drug Dev; 2015 Jan; 4(1):56-62. PubMed ID: 27128003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects.
    Kosoglou T; Reyderman L; Kasserra C; Jennings LK; Young S; Xuan F; Pei J; Maxwell SE; Schiller J; Meehan AG; Cutler DL
    Eur J Clin Pharmacol; 2012 Mar; 68(3):291-300. PubMed ID: 21969227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin.
    Kosoglou T; Zhu Y; Xuan F; Black L; Johnson-Levonas AO; Martinho M; Statkevich P; Cutler DL
    Eur J Clin Pharmacol; 2012 Nov; 68(11):1509-16. PubMed ID: 22476387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease.
    Arif SA; D'Souza J; Gil M; Gim S
    Am J Health Syst Pharm; 2015 Oct; 72(19):1615-22. PubMed ID: 26386102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vorapaxar for HIV-associated inflammation and coagulopathy (ADVICE): a randomised, double-blind, placebo-controlled trial.
    ADVICE study group
    Lancet HIV; 2018 Oct; 5(10):e553-e559. PubMed ID: 30257802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic drug evaluation of vorapaxar for secondary prevention after acute coronary syndrome.
    Perez-Rivera JA; Monedero-Campo J; Cieza-Borrella C; Ruiz-Perez P
    Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):339-350. PubMed ID: 28135897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of human liver cytochrome P450 enzymes involved in the metabolism of SCH 530348 (Vorapaxar), a potent oral thrombin protease-activated receptor 1 antagonist.
    Ghosal A; Lu X; Penner N; Gao L; Ramanathan R; Chowdhury SK; Kishnani NS; Alton KB
    Drug Metab Dispos; 2011 Jan; 39(1):30-8. PubMed ID: 20926621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with mild hepatic impairment.
    Butler K; Teng R
    J Clin Pharmacol; 2011 Jul; 51(7):978-87. PubMed ID: 20926753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar.
    Cho JR; Rollini F; Franchi F; Ferrante E; Angiolillo DJ
    Vasc Health Risk Manag; 2014; 10():177-88. PubMed ID: 24729713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet transfusion reverses bleeding evoked by triple anti-platelet therapy including vorapaxar, a novel platelet thrombin receptor antagonist.
    Cai TQ; Wickham LA; Sitko G; Michener MS; Raubertas R; Handt L; Chintala M; Seiffert D; Forrest M
    Eur J Pharmacol; 2015 Jul; 758():107-14. PubMed ID: 25857224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vorapaxar in the secondary prevention of atherothrombotic events.
    Morrow DA; Braunwald E; Bonaca MP; Ameriso SF; Dalby AJ; Fish MP; Fox KA; Lipka LJ; Liu X; Nicolau JC; Ophuis AJ; Paolasso E; Scirica BM; Spinar J; Theroux P; Wiviott SD; Strony J; Murphy SA;
    N Engl J Med; 2012 Apr; 366(15):1404-13. PubMed ID: 22443427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vorapaxar: a novel protease-activated receptor-1 inhibitor.
    Gurbel PA; Jeong YH; Tantry US
    Expert Opin Investig Drugs; 2011 Oct; 20(10):1445-53. PubMed ID: 21819272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.
    Tricoci P; Huang Z; Held C; Moliterno DJ; Armstrong PW; Van de Werf F; White HD; Aylward PE; Wallentin L; Chen E; Lokhnygina Y; Pei J; Leonardi S; Rorick TL; Kilian AM; Jennings LH; Ambrosio G; Bode C; Cequier A; Cornel JH; Diaz R; Erkan A; Huber K; Hudson MP; Jiang L; Jukema JW; Lewis BS; Lincoff AM; Montalescot G; Nicolau JC; Ogawa H; Pfisterer M; Prieto JC; Ruzyllo W; Sinnaeve PR; Storey RF; Valgimigli M; Whellan DJ; Widimsky P; Strony J; Harrington RA; Mahaffey KW;
    N Engl J Med; 2012 Jan; 366(1):20-33. PubMed ID: 22077816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro pharmacological characterization of vorapaxar, a novel platelet thrombin receptor antagonist.
    Hawes BE; Zhai Y; Hesk D; Wirth M; Wei H; Chintala M; Seiffert D
    Eur J Pharmacol; 2015 Sep; 762():221-8. PubMed ID: 26022529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vorapaxar for the reduction of atherothrombotic events.
    Diaz-Ricart M; Escolar G
    Drugs Today (Barc); 2014 Nov; 50(11):747-56. PubMed ID: 25525635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.